A study evaluating intestinal FDG accumulation on 18F-FDG-PET/MRI in patients taking imeglimin or metformin

A study evaluating intestinal FDG accumulation on 18F-FDG-PET/MRI in patients taking imeglimin or metformin - PET/MRI study with imeglimin or metformin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046509

Enrollment

Registered

2022-03-01

Start date

2022-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

PET/MRI scan in patients with metformin PET/MRI scan in patients with metformin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who agreed to participate in the study of the mechanism of action of imeglimin with the use of glucose clamp method in Japanese patients with type 2 diabetes mellitus (metformin-controled, randomized, open-label, parallel-group comparison study)

Exclusion criteria

Exclusion criteria: 1. patients with the following contraindications to Buscopan (butyl scopolamine bromide) patients with hemorrhagic colitis patients with angle-closure glaucoma patients with dysuria due to prostatic hypertrophy patients with severe heart disease patients with paralytic ileus patients with a history of allergy to this drug 2. patients with possible intestinal perforation or obstruction 3. patients with metalic device in the body that cannot be tested by PET/MRE 4. other patients who are judged unsuitable for this study by the investigator

Design outcomes

Primary

Measure	Time frame
FDG excretion into the intestinal tract by 18F-FDG-PET/MRE	—

Countries

Japan

Contacts

Public ContactKazuhiko Sakaguchi

Kobe University Department of Diabetes and Endocrinology

kzhkskgc@med.kobe-u.ac.jp078-382-5861

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026